News Sentiment

IMRX sentiment intelligence

Immuneering Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.11 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-1.5% over one week, +22.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know

Market Reaction

Balanced read

70/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend inactive 22.0% over four weeks
Fair value 19.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 35
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 10
Sahm 5
GlobeNewswire 5
simplywall.st 5
Investing.com 4
TradingView 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 16
Analyst action 5
Balance sheet 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
TipRanks Direct company coverage

Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors

Immuneering Corp. (IMRX) is conducting a Phase 3 clinical trial, MAPKeeper 301, to evaluate its drug atebimetinib combined with chemotherapy as a first-line treatment for metastatic pancreatic cancer. The study, which began in April 2026 and was last updated on May 5, 2026, aims

Tone
Positive 75/100
Event
Market update
Published
08 May 2026 15:38
Source
TipRanks
Sahm Direct company coverage

Insider Buyers At Immuneering Sitting On US$361k Profit

Insiders at Immuneering Corporation, including the Chairman of the Board, purchased shares worth US$721,000 over the past year, which are now valued at US$1.08 million, indicating a profit despite a recent stock drop. This insider buying suggests confidence in the company, though

Tone
Positive 66/100
Event
Earnings
Published
02 May 2026 13:08
Source
Sahm
Stock Titan Direct company coverage

Immuneering (IMRX) details 2026 virtual meeting, director votes and auditor ratification

Immuneering Corporation (IMRX) announced details for its virtual 2026 annual stockholder meeting, scheduled for June 11, 2026. Stockholders will vote on the election of two Class II directors, Peter Feinberg and Laurie B. Keating, for terms expiring in 2029, and the ratification

Tone
Neutral 50/100
Event
Market update
Published
21 Apr 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Immuneering Corp (IMRX) CPO acquires shares through employee stock plan

Immuneering Corp's Chief People Officer, Leah R. Neufeld, acquired 3,628 shares of Class A Common Stock on March 13, 2026, at $4.2925 per share through the company's 2021 Employee Stock Purchase Plan. This routine acquisition, part of an offering period from September 2025 to Mar

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Mar 2026 19:10
Source
Stock Titan
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: CAMP4 Therapeutics Corporation (CAMP), Owlet (OWLT) and Immuneering (IMRX)

Three healthcare companies, CAMP4 Therapeutics Corporation (CAMP), Owlet (OWLT), and Immuneering (IMRX), recently received bullish sentiments from analysts. Wedbush reiterated a Buy rating on CAMP4 with an $8.00 price target, Lake Street maintained a Buy on Owlet with a $14.00 pr

Tone
Positive 72/100
Event
Analyst action
Published
11 Mar 2026 18:09
Source
The Globe and Mail
Investing.com Direct company coverage

Immuneering director Schall buys $101k in shares

Immuneering Corp director Thomas J. Schall recently purchased 21,645 shares of Class A Common Stock for over $101,000. This insider transaction comes as Immuneering announced positive Phase 2a trial results for its pancreatic cancer drug, atebimetinib, and confirmed plans for a g

Tone
Positive 72/100
Event
Earnings
Published
11 Feb 2026 01:51
Source
Investing.com
Stock Titan Direct company coverage

140,000 stock options granted to Immuneering Corp (IMRX) chief business officer

Immuneering Corp's Chief Business Officer, Harold Eugene Brakewood, was granted 140,000 stock options on February 3, 2026, with an exercise price of $4.91 per share. These options will vest in equal monthly installments over four years, becoming fully exercisable by January 1, 20

Tone
Neutral 50/100
Event
Market update
Published
05 Feb 2026 16:40
Source
Stock Titan
Stock Titan Direct company coverage

IMRX Stock Price, News & Analysis

Immuneering Corporation (IMRX) is a clinical-stage oncology company listed on Nasdaq, focused on developing Deep Cyclic Inhibitors (DCIs) for cancer treatment. Its lead product candidate, atebimetinib, targets MAPK pathway-driven tumors, including pancreatic cancer and NSCLC, and

Tone
Positive 80/100
Event
Market update
Published
03 Feb 2026 16:58
Source
Stock Titan
Sahm Direct company coverage

Immuneering Director Acquires 1.8% More Stock

Immuneering Corporation's Director, Peter Feinberg, recently purchased US$87k worth of stock at US$4.35 per share, increasing his shareholding by 1.8%. This follows a larger purchase by Chairman Thomas Schall 12 months ago at a lower price. Insiders collectively own 14% of the co

Tone
Positive 65/100
Event
Market update
Published
17 Jan 2026 07:28
Source
Sahm
Sahm Direct company coverage

Looking Into Immuneering Corp's Recent Short Interest

Immuneering Corp.'s short interest has significantly increased by 43.1% since its last report, now standing at 10.92 million shares, which represents 19.49% of its available trading shares. This elevated short interest is higher than the average for its peer group and suggests a

Tone
Negative 39/100
Event
Market update
Published
15 Jan 2026 09:28
Source
Sahm
Investing.com Nigeria Direct company coverage

Immuneering director Feinberg buys $86k in shares By Investing.com

Immuneering Corp Director Peter Feinberg purchased 20,000 shares of Class A Common Stock for $86,904 on January 12, 2026, increasing his direct and indirect holdings. This insider purchase occurs after a significant stock drop, though the company's valuation appears slightly unde

Tone
Positive 66/100
Event
Market update
Published
14 Jan 2026 19:57
Source
Investing.com Nigeria
Investing.com Direct company coverage

Immuneering director Feinberg buys $86k in shares

Immuneering Corp (NASDAQ:IMRX) Director Peter Feinberg purchased 20,000 shares of Class A Common Stock for $86,904 on January 12, 2026, increasing his direct and indirect holdings significantly. This insider transaction follows a recent stock drop of over 50% but the stock remain

Tone
Positive 72/100
Event
Market update
Published
14 Jan 2026 12:57
Source
Investing.com